Go for the right left ventricular lead position at initial implantation of a cardiac resynchronization therapy device

Daniel Benjamin Fyenbo^{1

2}, Mads Brix Kronborg^{1

2}, Jens Cosedis Nielsen^{1

2}

Affiliations

Editorial

Daniel Benjamin Fyenbo et al. Heart Rhythm O2. 2022.

. 2022 Sep 20;3(5):464-465.

doi: 10.1016/j.hroo.2022.09.010. eCollection 2022 Oct.

Daniel Benjamin Fyenbo^{1

2}, Mads Brix Kronborg^{1

2}, Jens Cosedis Nielsen^{1

2}

No abstract available

Comment on

1. Glikson M., Nielsen J.C., Kronborg M.B., et al. ESC Scientific Document Group 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42:3427–3520. - PubMed
1. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845–1853. - PubMed
1. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–1549. - PubMed
1. Borgquist R., Mörtsell D., Chaudhry U., Brandt J., Farouq M., Wang L. Repositioning and optimization of left ventricular lead position in nonresponders to cardiac resynchronization therapy is associated with improved ejection fraction, lower NT-proBNP values, and fewer heart failure symptoms. Heart Rhythm O2. 2022;3:457–463. - PMC - PubMed
1. Fornwalt B.K., Sprague W.W., BeDell P., et al. Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation. 2010;121:1985–1991. - PMC - PubMed